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 ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Animal 
Assisted Therapy (AAT) using dogs is an effective treatment for positive and negative symptoms 
for adult inpatient schizophrenics. 
STUDY DESIGN: Systematic review of 3 articles published in English in peer reviewed journals 
between 2005-2009 
DATA SOURCES: Two randomized controlled trials and one allocation by minimization 
controlled trial comparing the effects of AAT using dogs on positive and negative symptoms of 
schizophrenia to control groups. All articles were found using PubMed and PROQuest 
OUTCOMES MEASURED: Focused questionnaires were given before and after AAT to 
analyze the effects on positive and negative symptoms.  
RESULTS: Chu et al. and Vilalta-Gil et al. showed improvement following treatment in positive 
symptoms. Vilalta-Gil et al. also showed improvement in negative symptoms. Nathans-Barel 
showed no improvement in positive or negative symptoms, but marked improvements in hedonic 
tone. 
CONCLUSIONS: The results of the three studies gave inconclusive evidence for the use of AAT 
in the treatment of positive and negative symptoms. Limitations in the study designs, such as size 
and lack of follow up, prevent the results from sufficiently identifying a relationship between 
AAT and positive and negative symptoms. However, the results encourage further study, 
especially when the relatively minimal risk of the intervention is considered. 
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INTRODUCTION 
 Schizophrenia is a complex, common and debilitating psychiatric disorder that is 
characterized by two types of symptoms, positive and negative. Positive symptoms are 
characterized by a disconnect from reality, such as hallucinations, delusions and deranged 
thoughts. Negative symptoms are characterized by disrupted emotions and behaviors such as flat 
affect, anhedonia and lack of communication. Schizophrenia has varying forms and degrees of 
severity but is often incapacitating, with more than half of individuals experiencing significant 
impairment in functioning throughout adulthood.
7
 It is the most common diagnosis amongst 
institutionalized individuals
3
, with 1/3 of individuals meeting the criteria for a diagnosis.
4
 
Schizophrenia affects 24 million people worldwide, with a prevalence of 7 per 1,000 and 
incidence of 3 in every 10,000 due to its chronicity.
4
  
Treatment and management costs are quite substantial due to the need for long term 
institutionalization and complex multidimensional therapies, with an estimated total cost of 
$62.7 billion (2002) in the US
5
, and  1.5-3% of the total national health care expenditures 
worldwide.
6
 These large costs make it prudent to search for cost effective treatment methods that 
work towards reducing symptomatology associated with the condition and allow them to 
function at a higher level, thus easing financial, family and institutional burden associated with 
treating institutionalized schizophrenics.  
The effects of schizophrenia can be widespread and require extensive care and clinical 
interventions. Standard pharmacological treatments using atypical antipsychotics (e.g. 
aripiprazol, clozapine) and typical antipsychotics (e.g. chlorpromazine, haloperidol) have been 
shown to improve positive symptoms, but are less efficacious with the treatment of negative 
symptoms. This is of clinical importance because negative symptoms have been shown to be 
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better predictors of long term disability than positive symptoms.
3
 Alternative approaches such as 
Animal Assisted Therapy (AAT) have been shown to improve social functioning and thus aid in 
the long term management and autonomy of schizophrenics.
1 
 Many aspects of schizophrenia are not well understood and are a source of continuing 
research. The exact etiology of schizophrenia is unknown and is likely without a unifying source; 
however research shows several different factors associated with the condition. There is evidence 
to support genetic inheritance as playing a role in development, but it is likely that multiple 
genes acting in concert are the cause and thus not easily used in predicting prevalence amongst 
families. Several genes have been linked with schizophrenia but each account for only a small 
proportion of cases.
7
 Structural abnormalities, such as enlarged lateral ventricles, and reduction 
in volume of the hippocampus, temporal and frontal lobes have been shown in effected 
individuals. Disruptions in several neurotransmitters, especially dopamine, play a role in the 
development of the disease and are important targets for pharmacologic therapy.
7
 Environmental 
stressors, such as; poor family support, physical and emotional neglect and abuse  have all been 
shown to precede initial onset of the disease process in children, as well as aggravate individuals 
with established disease. These stressful events trigger the hypothalamic-pituitary-adrenal (HPA) 
axis and cause chronically high levels of cortisol, which can lead to alterations of 
neurotransmitter activity and reductions of hippocampal volume.
7
 
Antipsychotic medications that lower dopaminergic activity diminish the severity and 
prevalence of psychotic symptoms, especially positive symptoms, but have varying degrees of 
motor side effects depending upon the specific agent that is used, with the newer atypicals 
having less harmful side effect profiles than the typical antipsychotics.
7
 Several psychosocial 
treatment methods currently exist that aim to improve interpersonal interactions, autonomy, and 
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reduce the prevalence of psychotic episodes. Cognitive behavior therapy, family therapy and 
stress management techniques have all shown promise as adjunctive therapies to pharmacologic 
treatments, though the wide variety in presentations of patients requires various treatment 
options.
7
 
Animal Assisted Therapy (AAT) has been shown to have several positive effects such as 
helping to improve socialization and communication while decreasing anger, depression, and 
anxiety in psychiatric patients.
8
 AAT also comes with very minimal risk, especially when 
compared to the large side effect profiles of the antipsychotic medications that are currently 
available. Fear of the animal, allergy, and underlying asthma conditions are among the limited 
number of factors that would hinder the use of this therapy.
8
 This paper evaluates three studies 
comparing the effects of regimented exposure to trained therapy dogs to control groups using 
clinical questionnaires to evaluate AAT's efficacy on positive and negative symptoms of 
institutionalized schizophrenics when used as an adjunctive therapy. 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not animal assisted 
therapy using dogs is an effective treatment for positive and negative symptoms for adult 
inpatient schizophrenics. 
METHODS 
 The population chosen was adult (>18 y/o) inpatients with clinically diagnosed 
schizophrenia. Interventions all involved the use of trained dogs for animal assisted therapy with 
variation amongst the studies regarding the specific methods used for AAT. Comparison groups 
looked at other institutionalized schizophrenics who were not receiving AAT. All studies used 
clinical questionnaires to study the effects of AAT on positive and negative symptoms of 
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schizophrenia. The questionnaires and specific symptoms being studied varied between the three 
papers. Two randomized controlled trials and one allocation by minimization-controlled trial 
were used. 
 All articles were published in English in peer reviewed journals. Articles were found by 
the author in PubMed and PROQuest using the keywords “schizophrenia” AND “animal 
assisted” OR “dog therapy”. Articles were selected based on relevance and that the outcomes of 
the studies mattered to patients (POEMs). Inclusion criteria were controlled studies using patient 
>18 y/o who were also institutionalized schizophrenics. Excluded from the review were studies 
looking at children <18y/o, outpatient schizophrenics and the use of animals other than dogs. The 
statistics used in the studies all used p-values.  
OUTCOMES MEASURED 
 Chu et al. looked at positive symptoms and negative symptoms (all assessed using an 
unnamed self-survey).  
Nathans-Barel et al. studied hedonic tone (Snaith-Hamilton Pleasure Scale (SHAPS)) 
negative symptoms (Schedule for the Assessment of Negative Symptoms (SANS)) and positive 
symptoms (Positive And Negative Syndrome Scale (PANSS)).   
Villalta-Gil et al. studied positive symptoms and negative symptoms (PANSS) 
RESULTS 
 Three studies compared the use of AAT with dogs on clinically diagnosed 
institutionalized schizophrenics who were 18 or older. The studies by Chu et al. and Vilalta-Gil 
et al. were both single blind randomized controlled trials and the Nathans-Barel et al. study was 
an allocation by minimization controlled trial. No intervention related negative effects or adverse 
reactions were reported in any of the 3 studies.
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Table 1: Demographics and Characteristics of Included Studies 
Study Type # pts Age 
(years) 
Inclusion criteria Exclusion 
criteria 
W/D Interventions 
Chu1 
(2009) 
RCT 30 <60 <60, ability to 
speak, read and 
write mandarin 
Chinese, 
diagnosis of 
schizophrenia for 
>10yrs, score >39 
on the schedule 
for the 
assessment of 
negative 
symptoms, no 
cognitive 
impairment 
Receiving 
any other 
experimental 
treatment 
during the 
study period 
3 Weekly 50min 
sessions, x8 
weeks, of loosely 
organized 
activities w/ 2 
medium sized 
trained therapy 
dogs 
Nathans2 
(2005) 
Allocation by 
minimization-
controlled 
trial 
20 19-62 
(mean 
39.9) 
Diagnosed 
chronic 
schizophrenia, 
inpatients in long-
term ward >2 
continuous years,  
Change in 
antipsychotic 
medications 
<6 months 
ago, allergies 
to dogs 
0 1hr therapy 
sessions, x10 
weeks, w/ female 
golden retriever. 
Patients 
interacted with 
the dog in a 
number of ways 
including but not 
limited to: 
playing, 
grooming, 
introducing the 
dog to new 
people, feeding 
and walking the 
dog  
Villalta-
Gil3 
(2009) 
RCT 21 >18 >10 years 
clinically 
diagnosed 
schizophrenia, 
>18 y/o, 
institutionalized 
during the 
program 
Mental 
retardation, 
neurological 
disorders, 
adverse 
psychological 
or physical 
reactions to 
animals 
3 Group therapy 
involving a 
female Labrador 
trained as a 
therapy dog. The 
sessions had the 
patients 
performing a 
number of 
different tasks 
involving the 
dog directly 
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Chu et al. studied 30 patients from a psychiatric institution in Taiwan, all of which were 
<60 and >18 years old, could speak, read and write mandarin Chinese, had a diagnosis of 
schizophrenia for >10yrs, score >39 on the schedule for the assessment of negative symptoms, 
and had no cognitive impairment. Excluded from the study were any patients who were receiving 
other experimental treatment during the study period. The 30 patients were randomly split into 2 
groups, with one receiving weekly 50 minute sessions with the dog for 8 weeks along with their 
regular treatment regimens and the other group receiving only their regularly scheduled 
treatment regimens. Sessions consisted of loosely organized activities w/ 2 medium sized trained 
therapy dogs. Self-reported questionnaires were given before and after the 8 week trial. Table 2 
shows the pre and post treatment scores and the corresponding p-value. Post treatment positive 
symptoms were shown to be significantly improved in the treatment group when compared with 
the control group using a Mann-Whitney U test (p-value = .005). Negative symptoms were not 
significantly improved (p-value = .097) 
Table 2: Change in Symptoms Pre and Post AAT Treatment 
Pre-treatment Post-treatment Pre-treatment Post-treatment p-value
Positive symptoms 14.88 8.46 15.85 16.54 0.005
Negative Symptoms 13.28 10.13 13.78 14.88 0.097
Treatment Group (mean) Control Group (mean)
 
 Nathans-Barel et al. studied 20 diagnosed schizophrenics living in a long term care ward 
of a hospital for a minimum of two continuous years. Excluded from the study were any 
individuals with a change in their antipsychotic medications within the last 6 months and 
individuals with an allergy to dogs.  The subjects were assigned to the treatment or control group 
on a minimization basis in order to reduce age and sex differences, with no reference to clinical 
or other factors. Both the treatment and control group received 10 weekly 1 hour sessions with 
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the same therapist, with the treatment group participating in activities with a well-trained dog. 
The treatment participants were given the choice of several activities to perform with the dog, 
including but not limited to: petting, feeding, cleaning, walking and making contact with the dog. 
The control group participated in similar activities, but without the dog. Pre and post treatment 
SHAPS, PANSS, and SANS questionnaires were administered and compared. Post treatment 
scores were compared using an ANCOVA. Positive and negative symptoms failed to show 
significant change compared to the control group as seen in table 3 (p-values = 0.82, 0.20 
respectively). Hedonic tone was shown to have significant change (p-value = 0.02) 
Table 3: Change in Symptoms Pre and Post AAT Treatment 
Pre Post Pre Post p-value F
Negative Symptoms 54 48.1 58.1 52.4 0.82 0.05
Positive Symptoms 17.9 16.3 15.8 13.3 0.2 1.79
Hedonic Tone 2.82 3.44 2.89 3.12 0.02 6.3
Treatment Group (mean) Control Group (mean) ANCOVA
 
 Villalta-Gil et al. studied 24 inpatients at Saint John of God-Mental Health Services 
Hospital in Barcelona Spain. For inclusion, patients had to be over 18 y/o, have diagnosed 
schizophrenia for >10 years, and be institutionalized. Excluded were those with mental 
retardation, neurological disorders or adverse psychological or physical reactions to animals. Of 
those selected, three patients declined to take part in the study prior to it beginning. Following 
baseline testing, participants were randomly assigned to the treatment (n=12) or control group 
(n=9). Both groups received 25 45 minute sessions, given twice a week of a group based therapy 
based on Integrated Psychological Treatment (IPT), with the treatment group receiving a 
modified version to allow for the use of the therapy dogs. Using the Wilcoxon signed-rank test, 
positive symptoms showed significant improvement following treatment in both the treatment 
(p-values = 0.005) and the control (p-value = 0.027) groups, as seen in Table 4. Negative 
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symptoms were significantly improved following treatment in the treatment group (p = 0.005) 
but not in the control group. There were no significant changes found when comparing the 
treatment group to the control group before or after treatment using the Mann Whitney U Test. 
Table 4: Changes in Symptoms Pre and Post Treatment 
Pre Post Z p Pre Post p-value Z
Negative Symptoms 28.92 19.36 -2.81 0.005 25.44 16.67 -1.89
Positive Symptoms 20.83 15.64 -2.81 0.005 22.67 17 0.027 -2.21
Treatment Group Control Group
 
DISCUSSION 
 This systematic literature review investigated whether or not animal assisted therapy 
could improve positive and negative symptoms for inpatient adult schizophrenic patients. The 
results obtained in these three studies are inconclusive and requires additional studies to further 
examine AAT’s efficacy for schizophrenia. Though this paper looked specifically at positive and 
negative symptoms of schizophrenia, the papers looked at several other factors. One observation 
that was noted by all researchers was that the patients receiving AAT expressed excitement, 
compassion and increased social interactions after starting their program. Such observations, 
though not always evident in the statistical analysis, should not be over looked.  
All three of the studies that were reviewed share some characteristics that limit their 
efficacy. All of the studies were small in size and lacked any follow up after the conclusion of 
the study. The outcomes that were measured are inherently subjective and require the completion 
of questionnaires to obtain objective data. Schizophrenics are also prone to bouts of psychosis 
which could affect the reliability of the questionnaires that were administered. Additionally due 
to the nature of the intervention, none of the studies were double blinded. 
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 In addition to the limitations listed above, the study by Chu et al. used a less structured 
method of animal therapy, known as Animal Assisted Activity (AAA) which has a more general 
goal of improving patient’s physical health and sense of well-being as opposed to AAT which 
has specific aims for each interaction between the patient and the animal. The Nathans-Barel et 
al. study was additionally limited by being an allocation by minimization study rather than an 
RCT. This makes the results of the study inherently weaker. Finally the Study by Villalta-Gil et 
al. had 3 patients drop out (14.3%) before the end of the trial. No mention is made of performing 
worst case analysis to account for the loss of these subjects. 
 AAT with dogs as an adjunctive therapy for schizophrenia has very few drawbacks and 
besides those with allergies to the animal, shows very little risk.
9
 When well trained dogs and 
trainers are used, the risk of injury to a patient by the dog is minimal. The initial cost of starting 
an AAT program can be large, 
9
 but is less with dogs than with larger animals like horses.  
CONCLUSIONS 
 Based off of the results highlighted in this review, AAT’s efficacy on positive and 
negative symptoms of inpatient schizophrenics is inconclusive. 2 of the 3 studies showed 
improvements with positive symptoms, while only 1 showed improvement of negative 
symptoms, though hedonic tone was significantly improved in 1 study, and is similar to negative 
symptomology. Larger and longer studies must be done to explore AAT’s efficacy in this 
population, but early studies show promise. All of the patients studied had diagnosed 
schizophrenia, but there were varying degrees of the disease amongst each group member. More 
strict regulation of the severity of the subjects’ disease state could potentially more accurately 
assess AAT’s efficacy. Additionally using other animals besides dogs could help to expand the 
range of possibilities for AAT in this population.
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Schizophrenia is a complex chronic condition that poses significant challenges in its 
management. Continued research in the use of adjunctive therapies such as AAT can help 
provide additional treatment options in order to improve patient care, lower costs and reduce 
unwanted side effects of antipsychotic medications. 
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